Background
Hypertensive Disorders of Pregnancy (HDP), including preeclampsia and gestational hypertension, complicate 5-10% of pregnancies and confer a 2-4 fold increased risk of future cardiovascular disease. Despite guidelines recommending postpartum blood pressure monitoring, real-world data on the long-term impact of early antihypertensive treatment remain scarce. This population-based study provides critical insights into the decade-long cardiovascular trajectories of 108,906 French women with HDP.
Study Design
The nationwide cohort analyzed health data from women delivering between 2010-2014, excluding those with pre-existing chronic hypertension. Researchers compared outcomes between 35,878 (33%) women receiving ≥1 antihypertensive medication within 30 days postpartum versus untreated peers. Primary endpoints included new-onset chronic hypertension, heart failure, coronary/cerebrovascular/peripheral artery diseases, and two composite cardiovascular outcomes over 10 years.
Key Findings
Stark Risk Differences
Treated women demonstrated substantially higher adjusted hazards for all outcomes: chronic hypertension (aHR=3.067, 95% CI 2.996-3.139), composite events including CH (aHR=3.025), and composite events excluding CH (aHR=1.451). The 10-year absolute risk for chronic hypertension reached 44% in treated women versus 18% in untreated women.
Temporal Risk Patterns
Extended Cox models revealed the highest hazard ratios occurred immediately postpartum (0-6 months: aHR=6.01 for CH), gradually declining but remaining elevated at 5-10 years (aHR=2.14). This suggests postpartum treatment serves as a marker for more severe HDP phenotypes rather than causing long-term risk.
Under-recognition of High-Risk Women
Nearly 20% of untreated women still developed chronic hypertension within 10 years, indicating current postpartum screening fails to identify many at-risk patients who could benefit from preventive strategies.
Expert Commentary
The findings underscore two critical gaps: (1) Lack of standardized protocols for postpartum cardiovascular risk stratification after HDP, and (2) Absence of long-term follow-up systems bridging obstetric and primary care. Dr. Eliza Miller (Columbia University, non-author) notes: ‘We’re discharging these women with a time bomb in their medical history but no coordinated mechanism to defuse it.’
Conclusion
This study provides population-level evidence that postpartum antihypertensive treatment strongly predicts long-term cardiovascular risk, with nearly half developing chronic hypertension within a decade. The 18% risk among untreated women reveals significant under-detection of high-risk cases. Findings advocate for: (1) Mandatory postpartum cardiovascular risk scoring systems, (2) Integrated obstetric-cardiology transition clinics, and (3) Research into optimal surveillance intervals and preventive therapies for this population.
